BDNF-TrkB-pathway research compound 7,8-Dihydroxyflavone (7,8-DHF) — high-purity reference material. Purity 98% min. Molecular formula C15H10O4. Physical form: Yellow crystalline powder. CAS Registry Number: 38183-03-8. Supplied in 100g, 500g, 1kg+ quantities …
| API name | 7,8-Dihydroxyflavone (7,8-DHF) |
| CAS Registry Number | 38183-03-8 |
| Therapeutic Category | Nootropics |
| API Technology | Synthetic / semi-synthetic (molecule-specific route) |
| Pharmacopoeial reference | USP · Ph. Eur. · IP · JP — per-buyer specification |
| Manufacturer | Longshine Boi-Tech Pvt. Ltd., Pune, India |
| Quality system | WHO-GMP · ISO 9001:2015 · ICH Q7 · ICH Q11 |
BDNF-TrkB-pathway research compound 7,8-Dihydroxyflavone (7,8-DHF) — high-purity reference material. Purity 98% min. Molecular formula C15H10O4. Physical form: Yellow crystalline powder. CAS Registry Number: 38183-03-8. Supplied in 100g, 500g, 1kg+ quantities from $1.50/g entry for laboratory research, analytical method development, and reference-standard applications. Research use only — not for human or animal consumption.
We supply 7,8-Dihydroxyflavone (7,8-DHF) to nootropics buyers across 50+ countries — generic drug manufacturers, CDMOs, hospital pharmacies, research institutions, and contract formulators. Letter of Authorization referencing our active DMF / CEP is issued at no charge to qualified buyers for ANDA, IND, NDA, EU Marketing Authorisation, MHRA UKMA, ANVISA, PMDA, and other regulatory pathways.
7,8-Dihydroxyflavone (7,8-DHF) is released against the buyer's chosen pharmacopoeia — USP, Ph. Eur., IP, or JP — with the destination market determining the default. The same lot can carry multiple pharmacopoeial certifications where the monographs align. Specification highlights routinely reported on each Certificate of Analysis (CoA) include:
Each 7,8-Dihydroxyflavone (7,8-DHF) batch ships with a full impurity profile — identified, qualified, and reported per ICH Q3A and Q3B guidelines. Process-related impurities are characterised in the DMF Restricted Part; degradation products are characterised through forced-degradation studies (acid, base, oxidation, thermal, photolysis) and reported in the stability dossier. ICH-compliant stability data is available on accelerated (40°C / 75% RH) and long-term (25°C / 60% RH or 30°C / 65% RH per ICH zone) conditions — typically 6 months accelerated and 24 to 36 months long-term depending on the molecule. Photostability per ICH Q1B option 2 is included.
Active regulatory dossiers maintained for 7,8-Dihydroxyflavone (7,8-DHF) (or compatible LoA support):
| Jurisdiction | Filing type | Documentation |
|---|---|---|
| United States | FDA Type II DMF | Letter of Authorization within 24 business hours; DMF number disclosed under MNDA |
| European Union | EDQM CEP or ASMF | CEP certificate or ASMF Restricted/Applicant's Part dossier |
| United Kingdom | MHRA UKMA / Windsor Framework | CEP-based recognition; UK-specific reference letter |
| Brazil | ANVISA RDC 359/2020 | Portuguese-language CMC package + reference letter |
| Canada | Health Canada DMF | Cross-reference of US FDA DMF |
| Japan | PMDA J-DMF | JP-grade release with Japanese-language label data |
| Korea | MFDS DMF | KP-grade release |
| GCC region | SFDA dossier support | Reference letters and CMC packages |
Each CoA carries the manufacturing date, batch number, retest date, and a QR-style traceability identifier linked to the batch manufacturing record. Per ICH Q7 requirements, retain samples are held for two years past the API expiry.